Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Retained Earnings: ¥612 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
67 GF Score
Price ¥15.70
GF Value ¥15.58
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Retained Earnings?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -1.63% 67 Retained Earnings is ¥612 Mil as of Jun. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 67/100 and a GF Value™ of ¥15.58 (Fairly Valued). The stock has 9 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jiangsu Lianhuan Pharmaceutical Co's retained earnings for the quarter that ended in Jun. 2026 was ¥612 Mil.

Jiangsu Lianhuan Pharmaceutical Co's quarterly retained earnings increased from Dec. 2025 (¥621 Mil) to Mar. 2026 (¥628 Mil) but then declined from Mar. 2026 (¥628 Mil) to Jun. 2026 (¥612 Mil).

Jiangsu Lianhuan Pharmaceutical Co's annual retained earnings increased from Dec. 2023 (¥712 Mil) to Dec. 2024 (¥745 Mil) but then declined from Dec. 2024 (¥745 Mil) to Dec. 2025 (¥621 Mil).


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Jiangsu Lianhuan Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Retained Earnings Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 539.15 633.35 712.27 745.19 621.45

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 679.76 684.72 621.45 627.88 611.99
SHSE:600513
67GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ¥612 Mil mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Retained Earnings of ¥612 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors.
Is Jiangsu Lianhuan Pharmaceutical Co's Retained Earnings too high?
Jiangsu Lianhuan Pharmaceutical Co's current Retained Earnings is ¥612 Mil. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Retained Earnings compare to ZTS?
Jiangsu Lianhuan Pharmaceutical Co's Retained Earnings of ¥612 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Retained Earnings is ¥612 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.58, compared to a current price of ¥15.70 — trading 0.8% above its estimated fair value. The current Retained Earnings is ¥612 Mil. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Retained Earnings is ¥612 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.70 is trading 0.8% above its estimated GF Value™ of ¥15.58. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600513:

  • Retained Earnings: ¥612 Mil
  • GF Value™: ¥15.58 vs. price of ¥15.70 (0.8% above fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
67GF Score

Get the complete analysis for SHSE:600513

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.70
Price
¥15.58
GF Value